Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $39.25

Key Points

• Genmab A/S has been rated as a "Moderate Buy" by ten brokerages, with six recommending buy and one strong buy rating.
• The average 12-month target price for Genmab A/S shares is $39.25, reflecting analysts' expectations for future stock performance.
• In its latest earnings report, Genmab A/S posted earnings per share of $0.54, exceeding expectations and showing a net margin of 37.53%.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $39.25.

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Zacks Research downgraded shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. Finally, HC Wainwright upped their price target on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, August 15th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GMAB. Squarepoint Ops LLC lifted its position in Genmab A/S by 1,235.0% during the fourth quarter. Squarepoint Ops LLC now owns 117,507 shares of the company's stock valued at $2,452,000 after purchasing an additional 108,705 shares during the last quarter. Vise Technologies Inc. grew its position in shares of Genmab A/S by 41.7% during the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company's stock valued at $269,000 after acquiring an additional 3,794 shares during the period. GTS Securities LLC bought a new position in shares of Genmab A/S during the fourth quarter worth $1,552,000. Mackenzie Financial Corp bought a new stake in Genmab A/S in the fourth quarter worth $689,000. Finally, Employees Retirement System of Texas bought a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $1,648,000. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Up 0.9%

Shares of Genmab A/S stock traded up $0.24 during trading on Friday, reaching $28.28. The company's stock had a trading volume of 1,874,979 shares, compared to its average volume of 1,414,093. The company has a market cap of $18.14 billion, a price-to-earnings ratio of 14.21, a P/E/G ratio of 1.65 and a beta of 0.93. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $28.75. The company has a 50-day simple moving average of $24.23 and a two-hundred day simple moving average of $21.82.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.